Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
amrubicin + erlotinib
- Development stage
- Unknown
- Lead developer
- Sumitomo Pharma
- Modality
- Small Molecules
- Administration
- Intravenous, Oral
01
Overview
Amrubicin + erlotinib is a combination therapy consisting of amrubicin, a fully synthetic 9-aminoanthracycline (anthracycline class cytotoxic agent), and erlotinib, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor. This combination has been investigated primarily for the treatment of previously treated advanced non-small cell lung cancer (NSCLC) patients with wild-type EGFR. Amrubicin acts as a DNA topoisomerase II inhibitor, leading to DNA damage and apoptosis in cancer cells. Erlotinib inhibits the EGFR tyrosine kinase, blocking downstream signaling pathways involved in tumor cell proliferation and survival. The rationale for combining these agents is based on observed synergistic effects in preclinical models and early-phase clinical trials showing improved progression-free survival compared to amrubicin monotherapy in this patient population[1][2].
- Other names
- amrubicin and erlotinibAMR + ERL
02
Targets
TOP2A (DNA topoisomerase II)EGFR (Epidermal growth factor receptor)
Beyond the preview
Go deeper on amrubicin + erlotinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on amrubicin + erlotinib.